Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IBI362 in metabolic dysfunction-associated steatohepatitis (MASH)
CTR20251306Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Jul 2025
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of mazdutide in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by InnoCare Pharma. Started Jul 2025; status: active.
02
Drugs
mazdutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20251306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251306.